#HAE #HereditaryAngioedema #Navenibart #RareDisease #PharmaNews #MedicalInnovation #AstriaTherapeutics #KakenPharmaceutical #ClinicalTrials #BioNews #AngioedemaNews

Astria Therapeutics Signs Licensing Deal with Kaken Pharmaceutical for HAE Treatment Development in Japan Astria Therapeutics, Inc. (NASDAQ: ATXS) a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has entered into an exclusive l

(NASDAQ: #ATXS)
#AstriaTherapeutics partners with Kaken Pharma to bring navenibart, a potential HAE treatment, to Japan with a $16M deal and milestone payments ahead.
prismmarketview.com/astria-thera...